Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 9/20 | 0.54 |
| ▸ | SELL | P14151 | 3/20 | 0.52 |
| ▸ | SELE | P16581 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658273 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658269 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658274 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL21537086 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777275 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658272 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777277 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658271 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL23957944 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658268 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8790654-B2 | Glycosylceramide adjuvant for saccharide antigens | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | claimed |
| US-20120269832-A1 | Mature Dendritic Cell Compositions and Methods of Culturing Same | COIMMUNE, INC. | 2012-10-25 | — | — | US | claimed |
| EP-2003969-B1 | MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME | ARGOS THERAPEUTICS INC (US) | 2011-05-25 | — | — | EP | claimed |
| US-7488491-B2 | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | NEW YORK UNIVERSITY (US) | 2009-02-10 | — | — | US | claimed |
| US-20080199487-A1 | Glycosylceramide Adjuvant for Saccharide Antigens | CHIRON SRL (IT) | 2008-08-21 | — | — | US | claimed |
| US-20080145931-A1 | Mature Dendritic Cell Compositions and Methods of Culturing Same | ARGOS THERAPEUTICS, INC. | 2008-06-19 | — | — | US | claimed |
| EP-1789059-A2 | GLYCOSYLCERAMIDE ADJUVANT FOR SACCHARIDE ANTIGENS | Novartis Vaccines and Diagnostics S.r.l. (IT) | 2007-05-30 | — | — | EP | claimed |
| WO-2006027685-A2 | GLYCOSYLCERAMIDE ADJUVANT FOR SACCHARIDE ANTIGENS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2006-03-16 | — | — | WO | claimed |
| EP-1434859-A2 | USE OF GLYCOSYLCERAMIDES AS ADJUVANTS FOR VACCINES AGAINST INFECTIONS AND CANCER | NEW YORK UNIVERSITY (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030157135-A1 | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | NEW YORK UNIVERSITY | 2003-08-21 | — | — | US | claimed |
| WO-2003009812-A2 | USE OF GLYCOSYLCERAMIDES AS ADJUVANTS FOR VACCINES AGAINST INFECTIONS AND CANCER | NEW YORK UNIVERSITY (US) | 2003-02-06 | — | — | WO | claimed |
| US-20260048115-A1 | PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS | SEQIRUS UK LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| EP-4183412-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-11891413-B2 | Vaccine against Klebsiella pneumoniae | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-02-06 | — | — | US | disclosed |
| EP-1551228-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | New York University (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2004-07-01 | — | — | US | disclosed |
| WO-2003105769-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030157135-A1 | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | NEW YORK UNIVERSITY | 2003-08-21 | — | — | US | disclosed |
| EP-1018548-A1 | CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING $g(a)-GLYCOSYLCERAMIDE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891413-B2 | Vaccine against Klebsiella pneumoniae | UBXN1, MLX, UBXN4 | APP 3158/4885SELP 584/4885SELL 1510/4885 |
| US-20080199487-A1 | Glycosylceramide Adjuvant for Saccharide Antigens | FUT5, SIGLEC7, FUT6 | APP 2757/4885SELP 289/4885SELL 127/4885 |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | UGT8, UGCG, SGMS1 | APP 3263/4885SELP 1036/4885SELL 2150/4885 |
| US-20030157135-A1 | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | UGCG, GBA1, GALC | APP 2576/4885SELP 978/4885SELL 980/4885 |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | APP 400/4885SELP 486/4885SELL 621/4885 |
| US-20260048115-A1 | PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS | SIGLEC9, CD209, SIGLEC7 | APP 1285/4885SELP 580/4885SELL 1488/4885 |
| US-20120269832-A1 | Mature Dendritic Cell Compositions and Methods of Culturing Same | CD40, CD40LG, CCR7 | APP 1368/4885SELP 1161/4885SELL 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.